29 results about "Red Blood Cell Count" patented technology

The embodiment of the invention relates to a sample analyzer and a sample analysis method. The sample analysis method comprises the following steps: sucking a to-be-detected blood sample; mixing at least one part of the blood sample to be tested, the hemolytic agent, the first dye and the second dye to prepare a test sample; in a single test, each particle in a measurement sample passes through an optical detection zone irradiated by excitation light one by one to acquire optical information including scattered light information, first fluorescence information, and second fluorescence information, the exciting light comprises light of a first wavelength capable of exciting the first dye and light of a second wavelength capable of exciting the second dye, and the second wavelength is larger than the first wavelength; and obtaining a white blood cell four-classification result and a counting result of a nucleated red blood cell group of the test sample based on the at least one kind of scattered light information, the first fluorescence information and the second fluorescence information. Therefore, the leukocyte classification result and the nucleated red blood cell counting result can be obtained at the same time in one test.

The application discloses an application of a TLR4 / NF-kappa B signal path inhibitor in preparation of a medicine for improving hematopoietic function of anemic inflammatory, relates to the technical field of biology and medicine, and discloses an application of the TLR4 / NF-kappa B signal path inhibitor in preparation of a medicine for improving hematopoietic function of anemic inflammatory, wherein the TLR4 / NF-kappa B signal path inhibitor is Danggui Buxue Decoction; the Danggui Buxue Decoction is composed of Astragalus and Angelica with a mass ratio of 5:1; the TLR4 / NF-kappa B signal path inhibitor is used for down-regulating expression of TLR4 protein and NF-kappa B protein in liver tissue; the improvement of hematopoietic function of anemic inflammatory includes increasing peripheral blood red blood cell count, white blood cell count, platelet count and hemoglobin level; the Danggui Buxue Decoction is used as the TLR4 / NF-kappa B inhibitor to improve anemic inflammatory, can down-regulate TLR4 / NF-kappa B expression, improve blood cells and hemoglobin, improve bone marrow pathology, reduce inflammatory factors and hepcidin, increase iron content, and provide a corresponding curative effect evaluation method, and provides a new choice for anemic inflammatory treatment.

The present invention provides a method for determining a mortality risk and / or probability of healthy lifespan of a cat; said method comprising determining the level of one or more biomarker(s) in one or more samples obtained from the cat, wherein the one or more biomarker(s) is selected from white blood cell count, haemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, red blood cell count, serum sodium, serum cholesterol, serum potassium, serum alkaline phosphatase, and / or serum GGT.

There remains a need for effective therapeutic agents for the treatment of TGFβ superfamily-associated disorders. [Solution] Polypeptides comprising an activin receptor type IIB (ActRIIB) ectodomain (ECD) variant are provided. In some embodiments, the polypeptides of the present disclosure comprise an ActRIIB-ECD variant fused to an Fc domain portion. The present disclosure also provides pharmaceutical compositions and methods using the polypeptides to treat diseases and conditions associated with TGF-β superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and / or low red blood cell levels (e.g., anemia).

The invention provides a construction method of a mouse model for inducing acute inflammatory anemia. An existing inflammatory anemia model is too long in construction period and cannot simulate the clinical phenomenon of acute anemia, the mouse model provided by the invention can induce the number of red blood cells and the hemoglobin level to be remarkably reduced through single Poly (I: C) stimulation for 36 hours, an acute anemia time window is accurately simulated, and a good foundation is laid for mechanism research of acute inflammatory anemia.

The present invention relates to a method for determining a mortality risk and / or probability of a healthy lifespan of a dog; said method comprising determining the level of one or more biomarker(s) in one or more samples obtained from the dog, wherein the one or more biomarker(s) is selected from white blood cell count, serum albumin, serum alkaline phosphatase, serum creatine kinase, haemoglobin, haematocrit, mean corpuscular haemoglobin, serum glucose, mean red cell volume, serum globulin, serum calcium, platelet count, and / or red blood cell count.

This application relates to a method, apparatus, computer equipment, and storage medium for selecting red blood cell detection regions. The method involves inputting a cell image into a pre-trained deep neural network to predict cell distribution and generate a first heatmap. Regions with more uniform cell distribution correspond to higher heatmap values. The first heatmap is then filtered using N preset filter boxes of different sizes to obtain N second heatmaps. The coordinates of the highest heatmap value in each second heatmap are extracted, and a selection box of the same size as the corresponding filter box is generated centered on the coordinates of the highest heatmap value on the cell image. Cell edges within each selection box are extracted, and the circular features of cells are detected based on these edges. Cells within the selection boxes are then screened based on these circular features, and the number of red blood cells within each selection box is counted. The selection box with the closest red blood cell count to the target count is selected as the red blood cell detection region, effectively improving the efficiency of red blood cell analysis and detection.

The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, and / or pulmonary hypertension.

The utility model relates to the technical field of in-vitro diagnosis and medical application, and discloses a lateral immunochromatography quantitative reagent which comprises a bottom plate, a sample pad is fixedly connected to the rightmost side of the upper portion of the bottom plate, a blood filtering pad is arranged on the left portion of the sample pad, a combining pad is arranged on the left portion of the blood filtering pad, and the combining pad is arranged on the right portion of the blood filtering pad. An NC membrane is arranged at the left part of the combination pad, a water absorption pad is arranged at the left part of the NC membrane, the NC membrane is coated with a detection antigen and is used for fixing a target substance in a sample, the sample pad is used for receiving and primarily treating the sample to be detected, and the sample pad and the blood filtering pad are fixed through an adhesive. According to the utility model, when whole blood and peripheral blood are detected, the content of folic acid in the body of a person to be detected can be obtained without centrifugation and red blood cell counting, so that folic acid detection can be realized in primary hospitals and village and town clinics.

This application relates to a blood cell analyzer and a red blood cell detection method. The blood cell analyzer includes: a sampling device for aspirating a blood sample to be tested; a sample preparation device for mixing a portion of the blood sample to be tested with a diluent to prepare a test sample; an impedance detection device including a counting cell and a detection component, wherein the counting cell is for the test sample to pass through, and the detection component is for acquiring the electronic signals of each particle in the test sample as it passes through the counting cell; and a processor configured to: acquire raw red blood cell volume distribution information based on the electronic signals of each particle in the test sample; acquire red blood cell agglutination information based on the raw red blood cell volume distribution information; and obtain the red blood cell count value of the blood sample to be tested based on the raw red blood cell volume distribution information and the red blood cell agglutination information. This enables the acquisition of an accurate red blood cell count value.

A device and method are taught for stimulating sympathetic nerves toward mitigating negative impacts to hematopoiesis. An autonomic nerve actuator and stimulator system with a graphic user interface (GUI), controller circuit which converts treatment parameters into a series of Building Block Waveforms (BBW) which are output to Current / Voltage Driver Circuitry (CDC) whose electrical stimulus (ES) outputs are coupled to one or more electrodes and / or electrode arrays positioned proximal specific nerve situations. The use of this in combination with conventional chemotherapy treatments, such as use of carboplatin, was found to significantly enhance hematopoiesis, with improvements in white and red blood cell counts, platelet concentration and hemoglobin concentration, in addition to other measurable characteristics which increased survival rates in the experimental groups tested.

The invention relates to the crossing field of medical image processing and artificial intelligence technology, in particular to a bone marrow cell morphology artificial intelligence analysis method and system, and the method comprises the steps: obtaining a multi-view high-resolution image of a bone marrow smear and / or a peripheral blood smear under the oil immersion magnification, and carrying out the preprocessing; carrying out red blood cell coarse segmentation and fine classification through a cascade deep network, and identifying target-shaped, broken, teardrop-shaped and elliptical red blood cells; correcting broken red blood cell counting by adopting a fragment aggregation correction algorithm; and calculating an MCI value in combination with blood routine test data, and carrying out weighted fusion on the MCI value and the abnormal red blood cell proportion to generate a thalassemia screening comprehensive score. Therefore, the problems of low manual identification efficiency, insufficient abnormal red blood cell identification accuracy, large broken red blood cell counting deviation, difficulty in distinguishing multiple types of abnormal red blood cells, lack of organic combination with clinical diagnosis indexes and the like are solved, and the efficiency and accuracy of morphological analysis of bone marrow cells are improved; and a reliable basis is provided for diagnosis of diseases such as thalassemia.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to application of a qi-tonifying and blood-maintaining preparation in preparation of a medicine for treating thalassemia. Researches show that the preparation for tonifying qi and maintaining blood is used for treating thalassemia and can effectively improve the anemia state and iron metabolism disorder of patients. Specifically, the medicine can significantly improve the hemoglobin level, increase the red blood cell count and the red blood cell average volume, and improve the serum iron content, the ferritin content and the reticulocyte proportion. The results show that the qi-tonifying and blood-maintaining preparation has the effect of promoting the bone marrow hematopoiesis function and can regulate and optimize the iron metabolism process. The invention provides an economical, effective and convenient treatment scheme for the thalassemia patient.

The embodiment of the invention discloses an auxiliary screening method and system for thalassemia and a storage medium. The method comprises the following steps: acquiring blood routine data of a patient to be subjected to thalassemia screening, and extracting model input data from the blood routine data of the patient; wherein the model input data comprises an average red blood cell volume (MCV), a red blood cell count (RBC) per liter, a hematocrit (Hct) and a red blood cell distribution width (RDW); and inputting the model input data into a pre-trained thalassemia prediction model for prediction, and outputting a thalassemia gene mutation carrying occurrence probability. According to the method, the model is adopted for screening the thalassemia, the model can predict the thalassemia gene mutation carrying occurrence probability only by inputting four red blood cell numerical values in a blood routine result, and compared with an existing screening means, the method is faster and lower in cost.

The present invention discloses the use of methyl α-D-glucopyranoside in the preparation of thalassemia therapeutic drugs. Comprehensive analysis shows that when methyl α-D-glucopyranoside was intraperitoneally injected into β-thalassemia mice, it was found that methyl α-D-glucopyranoside was one of the metabolites with the largest down-regulation amplitude, and had multiple beneficial effects on Th3 / + mice, including increasing the total red blood cell count, hemoglobin level and hematocrit, and reducing the coefficient of variation of the red blood cell volume distribution width; reducing the iron content in the liver, splenomegaly and iron content in the spleen; increasing the GSH / GSSG ratio, reducing the ROS level, reducing the apoptosis rate of peripheral blood cells, and increasing the lifespan of red blood cells. After GP treatment, the ineffective hematopoiesis, anemia and iron overload of thalassemia mice were effectively alleviated without obvious toxic side effects. The treatment is convenient to implement, and GP is cheap and easy to store.

The invention relates to the field of biological detection, in particular to a marker and application thereof in construction of a preeclampsia prediction model. The invention provides a marker, which comprises a red blood cell index and an inflammation marker; the red blood cell indexes comprise red blood cell count, hemoglobin, hematocrit, average red blood cell volume, average red blood cell hemoglobin and red blood cell distribution width variable coefficient; the inflammatory markers comprise leukocytes, neutrophils, lymphocytes, monocytes, platelets, eosinophils, platelet hematocrit, a systemic inflammatory response index and a systemic immune inflammatory index. The invention develops an efficient and easily available preeclampsia prediction tool, realizes early recognition and management of preeclampsia, and finally reduces maternal and infant complications.

To provide polypeptides and pharmaceutical compositions comprising activin type IIB receptor variants.SOLUTION: The polypeptide of the present invention comprises an extracellular activin type IIB receptor (ActRIIB) mutant comprising an amino acid sequence consisting of a specific sequence, wherein the C-terminus of the ActRIIB mutant is fused to a human IgG1Fc domain monomer. The invention also features pharmaceutical compositions and methods of using the same to treat diseases and conditions involving muscle weakness and atrophy, bone damage, low red blood cell levels (e.g., anemia or blood loss), fibrosis, and / or pulmonary hypertension.SELECTED DRAWING: Figure 2

The described technology can include methods of treating a population of red blood cells (RBCs) in an individual, particularly a chronic kidney disease (CKD) patient with renal anemia, by reducing the amount of a Piezo1 chemical agonist in the patient's blood. In one embodiment, a method of treating a patient with renal anemia can include increasing RBC lifespan of a population of RBCs in the patient by reducing Piezo1 channel activation duration of at least a portion of the population of RBCs by reducing the amount of a target uremic compound in the patient's blood, the target uremic compound having a form that prolongs Piezo1 channel activation duration, wherein the amount of the target uremic compound can be reduced by selectively removing at least a portion of the target uremic compound from the patient's blood. Other embodiments are also described.

The application discloses a composition for improving adverse reactions of chemotherapy and a preparation method, application and product thereof, and particularly relates to the technical field of drugs.The composition of the application comprises raw materials including turtles, soft-shelled turtles, deer antlers, sea cucumbers, sand ginger, dried orange peel and hawthorn; the composition is obtained by enzymolysis of alkaline protease and flavor protease, can significantly reduce the tumor volume of tumor-bearing animals, increase the DNA content of bone marrow of chemotherapy animals, and significantly increase the white blood cell count and red blood cell count in the peripheral blood of chemotherapy animals.The composition of the application is used in the preparation of related products for improving adverse reactions of chemotherapy, and the prepared products are easy to be absorbed and have a remarkable improvement effect on adverse reactions of chemotherapy.

The present invention provides the use of 18β-glycyrrhetinic acid for improving the hematopoietic capacity of renal anemia. The present invention discovers and verifies for the first time that 18β-glycyrrhetinic acid stimulates the production of endogenous EPO, thereby improving the body's hematopoietic capacity. Short-term supplementation of 18β-glycyrrhetinic acid can significantly increase the level of erythropoietin, thereby promoting the production of reticulocytes. Long-term supplementation of 18β-glycyrrhetinic acid can improve indicators such as red blood cell count and alleviate the symptoms of renal anemia. The present invention provides a natural, safe, and highly effective active ingredient that improves the body's hematopoietic capacity, provides a scientific basis for basic research on drugs for the clinical treatment and prevention of renal anemia, and has significant application value.

The invention relates to a composite peptide nutritional composition as well as a preparation method and application thereof, and belongs to the technical field of functional foods. The composite peptide nutritional composition comprises a hematopoietic function regulating system (such as cattle spleen peptide, blood protein polypeptide and salmon hydrolyzed protein peptide), an iron metabolism balance regulating system (concentrated hawthorn clear juice) and a nutrition absorption promoting system (endothelium corneum gigeriae galli peptide and pericarpium citri reticulatae powder) which have a synergistic effect. The traditional Chinese medicine composition does not contain an exogenous iron agent, and aims to improve malnutrition caused by chronic hemolytic diseases such as thalassemia. The uniformity and the stability of the product are guaranteed through a specific proportioning and a staged mixing preparation process. Animal experiments show that the composition can significantly improve hemoglobin and red blood cell count of beta-thalassemia model mice, effectively control serum iron and liver iron accumulation levels of the mice, show unique advantages of efficient hematopoiesis and low iron accumulation, and has broad application prospects. And a new nutrition support scheme is provided for improving anemia and abnormal iron metabolism conditions caused by chronic hemolysis.

To provide a technique that enables prediction of weight loss of a subject through increased exercise.SOLUTION: A method of the present invention is for qualitatively predicting weight loss of a subject through increased exercise and comprises an acquisition step of acquiring at least one indicator selected from a group consisting of: physical indicators indicative of at least either of a physique and body composition of the subject, consisting of MQP (Muscle Quality Point), weight, trunk fat-free mass, and trunk muscle mass; and blood indicators measured from a blood sample of the subject, consisting of the blood red cell count and hematocrit value.SELECTED DRAWING: None

OF THE INVENTION USE OF VDAC AND LAMP1 AS MARKERS FOR DETECTING POCKED RED BLOOD CELLS Counting vacuole-containing RBC (pocked-RBC) is a robust marker of defective spleen function but requires the expertise of fewer and fewer specialized laboratory technicians. Now the inventors have identified VDAC and LAMP1 as markers for detecting pocked red blood cells. In particular, after performing a proteomic analysis, the inventors confirmed the presence of these proteins in splenectomized subjects by western blot. RBC of splectomized and control subjects were then marked with antibodies LAMP1 or VDAC and passed to cytometry. RBC from control subjects did not have labelling but there were RBC marked for splenectomized subjects. RBC labelling were then observed in DIC and pocked cells with vacuoles marked were quantified. No marked vacuole was observed in control subjects whereas between 4 and 33% of pocked cells had at least one vacuole marked with antibodies LAMP1 or VDAC. Since, these proteins are not found in control subjects, it is therefore possible to use this markers for detecting pocked RBCs and thus splenectomized subjects.

The invention discloses a chronic kidney disease interstitial fibrosis and cellular crescent body prediction model and application thereof. The prediction model comprises a kidney interstitial fibrosis prediction model and a cellular crescent body prediction model. The renal interstitial fibrosis prediction model is Logit (P1) =-0.035 * estimated glomerular filtration rate (ml / min / 1.73 m < 2 >) + 0.030 * albumin (g / L)-0.039 * hematocrit (%) + 0.036 * RBC distribution width SD (fL)-0.212 * CD4 + / CD8 + T lymphocyte ratio + 0.313; wherein P1 is a severe renal interstitial fibrosis probability value; the cell crescent body prediction model is Logit (P2) =-0.032 * age (age)-0.766 * sex-1.047 * high density lipoprotein (mmol / L)-0.011 * estimated glomerular filtration rate (ml / min / 1.73 m < 2 >)-0.233 * ln (CD3 + CD4 + T lymphocyte count) (piece / l) + 0.670 * ln (urine erythrocyte count) ( / l) + 1.530; wherein P2 is a cellular crescent body formation probability value. The prediction model provided by the invention greatly improves the prediction ability of renal interstitial fibrosis and cellular crescent body, and has significant clinical application value.

This invention provides a method for determining the biological age, risk of death, and / or probability of healthy lifespan of a dog; the method comprising: a) determining the biological age, risk of death, and / or probability of healthy lifespan of a dog using the levels of one or more biomarkers selected from one or more samples obtained from the dog, wherein the one or more biomarkers are selected from white blood cell count, serum albumin, serum alkaline phosphatase, serum creatine kinase, hemoglobin, hematocrit, mean corpuscular hemoglobin, serum glucose, mean corpuscular volume, serum globulin, serum calcium, platelet count, and / or red blood cell count; and b) determining the biological age, risk of death, and / or probability of healthy lifespan of a dog using DNA methylation profiles from the dog.

Disclosed is an analysis system comprising: a blood cell analyzer configured to measure at least CBC items including white blood cell count, red blood cell count, hemoglobin amount, hematocrit value, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, and platelet count; a blood coagulation analyzer; and a transporter having a transport path configured to transport a sample to a first acquisition position on which the sample is acquired by the blood cell analyzer and a second acquisition position on which the sample is acquired by the blood coagulation analyzer, wherein the blood cell analyzer, the blood coagulation analyzer, and the transporter are arranged in positions and orientations that allow accesses from at least one position along one side of the transport path.

Disclosed is an analysis system comprising: a blood cell analyzer configured to measure at least CBC items including white blood cell count, red blood cell count, hemoglobin amount, hematocrit value, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, and platelet count; a blood coagulation analyzer; and a transporter configured to transport a sample to a first acquisition position on which the sample is acquired by the blood cell analyzer and a second acquisition position on which the sample is acquired by the blood coagulation analyzer, the transporter having a first side and a second side opposite to the first side, wherein the blood cell analyzer and the blood coagulation analyzer are arranged along the first side of the transporter, and the blood cell analyzer, the blood coagulation analyzer, and the transporter are arranged in positions and orientations that allow accesses from the second side of the transporter.

This disclosure is directed to devices, systems, and techniques for determining cardiac flow rate. An example medical device is configured to be at least substantially entirely inserted into a vasculature of a patient. The medical device includes an elongated housing and a first optical sensor configured to sense a first red blood cell count and generate a first signal indicative of the first red blood cell count. The medical device includes a second optical sensor configured to sense a second red blood cell count and generate a second signal indicative of the second red blood cell count, the second optical sensor being longitudinally displaced from the first optical sensor. The medical device also includes processing circuitry configured to determine a cardiac flow rate based on a first signal and the second signal.